MD Relative Valuation
MD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MD is overvalued; if below, it's undervalued.
Historical Valuation
Pediatrix Medical Group Inc (MD) is now in the Undervalued zone, suggesting that its current forward PE ratio of 8.39 is considered Undervalued compared with the five-year average of 11.18. The fair price of Pediatrix Medical Group Inc (MD) is between 21.02 to 33.20 according to relative valuation methord. Compared to the current price of 15.50 USD , Pediatrix Medical Group Inc is Undervalued By 26.28%.
Relative Value
Fair Zone
21.02-33.20
Current Price：15.50
26.28%
Undervalued
8.39
PE
1Y
3Y
5Y
Trailing
Forward
6.04
EV/EBITDA
Pediatrix Medical Group Inc. (MD) has a current EV/EBITDA of 6.04. The 5-year average EV/EBITDA is 9.01. The thresholds are as follows: Strongly Undervalued below 4.09, Undervalued between 4.09 and 6.55, Fairly Valued between 11.47 and 6.55, Overvalued between 11.47 and 13.93, and Strongly Overvalued above 13.93. The current Forward EV/EBITDA of 6.04 falls within the Undervalued range.
6.74
EV/EBIT
Pediatrix Medical Group Inc. (MD) has a current EV/EBIT of 6.74. The 5-year average EV/EBIT is 10.77. The thresholds are as follows: Strongly Undervalued below 4.83, Undervalued between 4.83 and 7.80, Fairly Valued between 13.73 and 7.80, Overvalued between 13.73 and 16.70, and Strongly Overvalued above 16.70. The current Forward EV/EBIT of 6.74 falls within the Undervalued range.
0.63
PS
Pediatrix Medical Group Inc. (MD) has a current PS of 0.63. The 5-year average PS is 0.76. The thresholds are as follows: Strongly Undervalued below 0.12, Undervalued between 0.12 and 0.44, Fairly Valued between 1.08 and 0.44, Overvalued between 1.08 and 1.40, and Strongly Overvalued above 1.40. The current Forward PS of 0.63 falls within the Historic Trend Line -Fairly Valued range.
7.06
P/OCF
Pediatrix Medical Group Inc. (MD) has a current P/OCF of 7.06. The 5-year average P/OCF is 12.86. The thresholds are as follows: Strongly Undervalued below -5.51, Undervalued between -5.51 and 3.68, Fairly Valued between 22.05 and 3.68, Overvalued between 22.05 and 31.23, and Strongly Overvalued above 31.23. The current Forward P/OCF of 7.06 falls within the Historic Trend Line -Fairly Valued range.
8.03
P/FCF
Pediatrix Medical Group Inc. (MD) has a current P/FCF of 8.03. The 5-year average P/FCF is 15.98. The thresholds are as follows: Strongly Undervalued below -15.07, Undervalued between -15.07 and 0.46, Fairly Valued between 31.50 and 0.46, Overvalued between 31.50 and 47.03, and Strongly Overvalued above 47.03. The current Forward P/FCF of 8.03 falls within the Historic Trend Line -Fairly Valued range.
Pediatrix Medical Group Inc (MD) has a current Price-to-Book (P/B) ratio of 1.50. Compared to its 3-year average P/B ratio of 1.28 , the current P/B ratio is approximately 17.38% higher. Relative to its 5-year average P/B ratio of 1.79, the current P/B ratio is about -16.12% higher. Pediatrix Medical Group Inc (MD) has a Forward Free Cash Flow (FCF) yield of approximately 18.83%. Compared to its 3-year average FCF yield of 12.14%, the current FCF yield is approximately 55.04% lower. Relative to its 5-year average FCF yield of 10.22% , the current FCF yield is about 84.21% lower.
1.50
P/B
Median3y
1.28
Median5y
1.79
18.83
FCF Yield
Median3y
12.14
Median5y
10.22
Competitors Valuation Multiple
The average P/S ratio for MD's competitors is 1.19, providing a benchmark for relative valuation. Pediatrix Medical Group Inc Corp (MD) exhibits a P/S ratio of 0.63, which is -46.99% above the industry average. Given its robust revenue growth of -7.03%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of MD increased by 42.73% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 4.10 to 11.38.
The secondary factor is the Revenue Growth, contributed -7.03%to the performance.
Overall, the performance of MD in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Pediatrix Medical Group Inc (MD) currently overvalued or undervalued?
What is Pediatrix Medical Group Inc (MD) fair value?
How does MD's valuation metrics compare to the industry average?
What is the current P/B ratio for Pediatrix Medical Group Inc (MD) as of Aug 14 2025?
What is the current FCF Yield for Pediatrix Medical Group Inc (MD) as of Aug 14 2025?
What is the current Forward P/E ratio for Pediatrix Medical Group Inc (MD) as of Aug 14 2025?